The primary objectives are to assess the effect of myo-inositol on its clinical improvement by assessing the restoration of regular menstrual cycles, hormonal parameters (follicle-stimulating hormone (FSH), luteinizing hormone (LH), and LH/FSH ratio), and metabolic parameters (fasting blood sugar (FBS), serum fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) index). The secondary objective is to observe any side effects of the drug. Here, PLOD1 is linked to Insulin resistance.